In a study comparing three immunomodulatory agents in patients with severe Behçet disease, adalimumab combined with corticosteroids was more effective in preventing uveitis relapse compared to cyclosporine and interferon alfa-2a. Patients receiving adalimumab had a lower relapse rate and later occurrence of relapse compared to those on cyclosporine or interferon alfa-2a. Adalimumab also had a more favorable safety profile. The study suggests prioritizing adalimumab for patients with severe uveitis. Limitations include the open-label design and potential biases, as well as the limited generalizability to patients previously treated with anti-TNF therapy. The study was funded by various sources, and one author disclosed receiving research grants from specific companies.
Source link
Adalimumab Tops Cyclosporine in Preventing Uveitis Relapse
